Yannick Quesnel

Yannick Quesnel

Auto-generated profile, based on publicly available information

Yannick Quesnel

Kokuma Charleroi Belgium

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2023 in EMBO Reports
Verified
Journal Article
Open access
GDGilles Dinsart
Gilles Dinsart
MLMorgane Leprovots
Morgane Leprovots
ALAnne Lefort
Anne Lefort
FLFrédérick Libert
Frédérick Libert
YQYannick Quesnel
Yannick Quesnel
MGMarie-Isabelle Garcia
Marie-Isabelle Garcia
The gastrointestinal epithelium constitutes a chemosensory system for microbiota-derived metabolites such as short-chain fatty acids (SCFA). Here, we investigate the spatial distribution of Olfr78, one of the SCFA receptors, in the mouse intestine and study the transcriptome of colon enteroendocrine cells expressing Olfr78. The receptor is predominantly detected in the enterochromaffin and L subtypes in the proximal and distal colon, respectively. Using the Olfr78-GFP and VilCre/Olfr78flox transgenic mouse lines, we show that loss of epithelial Olfr78 results in impaired enterochromaffin cell differentiation, blocking cells in an undefined secretory lineage state. This is accompanied by a reduced defense response to bacteria in colon crypts and slight dysbiosis. Using organoid cultures, we further show that maintenance of enterochromaffin cells involves activation of the Olfr78 receptor via the SCFA ligand acetate. Taken together, our work provides evidence that Olfr78 contributes to colon homeostasis by promoting enterochromaffin cell differentiation.

17 June 2026 in Dermatological Reviews
Verified
Journal Article
Closed access
YQYannick Quesnel
Yannick Quesnel
Michael H. GoldMichael H. Gold
Michael H. Gold

23 September 2026 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
PDF file
YQYannick Quesnel
Yannick Quesnel
Michael H. GoldMichael H. Gold
Michael H. Gold
Purpose: Saponins are amphiphilic glycosides found in plants. They have long been used in traditional Asian remedies for their anti‐inflammatory, protective, and rejuvenating properties. One representative, Glucuronyl Glucosyloleanolate (GGO), was recently discovered using a combination of artificial intelligence and experimental testing as a depigmenting agent. Its safety has been verified in humans during a patch test on 12 volunteers, followed by an HRIPT study on 100 volunteers. Finally, its depigmenting efficacy has been demonstrated after a clinical trial on 60 volunteers. Methods: A 48‐h patch test was conducted on 12 volunteers using the pure compound. HRIPT: a patch with 0.1% GGO in mineral oil was applied to 100 volunteers repeatedly over 3 weeks. After a 2‐week rest, a single patch was applied again to the induction site and to a new, untreated site for the challenge phase. Clinical trial: monocentric blind study of GGO (0.01% weight) versus placebo on a multi‐ethnic panel with pigmentation spots. Results: Safety: No skin irritation or adverse effects were observed in the patch test assay confirming the product's excellent safety. On the 100 volunteers, during the induction period, no reaction of irritation was observed after 3 weeks and during the challenge phase, no allergic reaction was observed. Based on these results, GGO demonstrated very good skin compatibility and does not show a sensitizing effect. Efficacy: all subgroups showed significant depigmentation from Day 21 onwards, which continued to increase in a similar manner to that observed with localized depigmentation. After 84 days, the level of depigmentation achieved was 10% on Asian, 14% on Caucasian and North African skin, and 24% on black skin. Dark Pigmentation spots on Asian and Caucasian skin depigmented at a rate 34% faster than the overall skin tone, resulting in their visual fading Conclusion: Glucuronyl Glucosyloleanolate, identified through AI‐enhanced biopharma strategies, shows strong skin‐brightening efficacy and safety. It depigments dark spots faster than skin tone brightening in an 84‐day clinical trial. Non‐irritant and potent at low doses, it promises broad cosmetic and medical applications (melasma). Future investigations should assess its anti‐aging and antioxidative potential to broaden its scope of application.

24 August 2026 in International Journal of Clinical Dermatology
Verified
Journal Article
Open access
PDF file
YQYannick Quesnel
Yannick Quesnel
Michael H. GoldMichael H. Gold
Michael H. Gold
Most of the depigmenting active ingredients currently in use work by inhibiting the catalytic activity of tyrosinase, and several of them are now subject to increasingly stringent regulatory and tolerance requirements. Glucuronylglucosyloleanolate (GGO), a natural triterpene saponin, was identified from public compound databases using an AI-based discovery platform combining in-silico predictions, physchem parameters and market requirements; and was subsequently subjected to a series of stepwise experiments. In normal human epidermal melanocytes, GGO reduced melanin production by up to 86% at a concentration of 2 µg/mL without any loss of viability; in one benchmark, it scored ahead of hydroquinone, kojic acid, niacinamide and tranexamic acid on melanin reduction. An in vitro assay on melanocyte tyrosinase showed no inhibition between 0.3 and 100 µM, indicating that the compound acts on enzyme expression rather than catalysis, and that it may also interfere with melanosome transfer. In UV-stimulated human explants, melanin content decreased by 45% and tyrosinase expression was reduced by a factor of 2.4 compared with controls, whilst tissue integrity was preserved. Safety was assessed at three levels: a 48-hour semi-occlusive patch test with the pure compound on 12 volunteers yielded an average irritation index of 0.00; the validated GARD®skin test revealed no sensitizing potential up to 0.4 g/L; and a repeated-challenge test in humans (HRIPT), carried out on over 100 volunteers at a concentration ten times higher than the clinical dose, did not result in any irritant or allergic reactions. Clinical efficacy was assessed in a randomized, single-blind, placebo-controlled trial, in which 60 volunteers, stratified according to Fitzpatrick phototype, applied 0.01% GGO or a placebo twice daily for 84 days. The individual typology angle increased significantly from day 21 onwards and continued to rise until day 84, reaching 11% in phototype III, 14% in phototype IV and 24% in phototype V, with no plateau observed at the end of the study. Hyperpigmented spots responded earlier and more rapidly than the surrounding skin, lightening approximately 34% faster to achieve a 17% reduction in patch intensity by day 84 and a measurable reduction in contrast compared with the adjacent skin. GGO therefore reduces the expression of enzymes involved in melanogenesis, a mechanism distinct from that of ingredients currently on the market, while also restricting pigment distribution, an effect reported in the literature. GGO achieves clinically significant depigmentation of both the overall complexion and localized hyperpigmentation at a concentration of 0.01%, making it far more potent than all competing products.